178 related articles for article (PubMed ID: 1618703)
1. Kinetic analysis of combination effect of navelbine (KW-2307) with cisplatin against human lung adenocarcinoma PC-12 cells in culture.
Gomi K; Ohno H; Nomura K; Okabe M; Kobayashi K; Niitani H
Jpn J Cancer Res; 1992 May; 83(5):532-9. PubMed ID: 1618703
[TBL] [Abstract][Full Text] [Related]
2. [Results of a randomized study comparing combination of navelbine-cisplatin to combination of vindesine-cisplatin and to navelbine alone in 612 patients with inoperable non-small cell lung cancer].
Le Chevalier T; Brisgand D; Pujol JL; Douillard JY; Monnier A; Rivière A; Chomy P; Le Groumellec A; Ruffie P; Gottfried M; Gaspard MH; Chevreau C; Alberola V; Cigolari S; Besson F; Martinez A; Besenval M; Berthaud P; Tursz T
Bull Cancer; 1996 May; 83(5):385-94. PubMed ID: 8680091
[TBL] [Abstract][Full Text] [Related]
3. Combination effect of navelbine (vinorelbine ditartrate) with cisplatin against murine P388 leukemia and human lung carcinoma xenografts in mice.
Ashizawa T; Asada M; Kobayashi E; Okabe M; Gomi K; Hirata T
Anticancer Drugs; 1993 Oct; 4(5):577-83. PubMed ID: 8292816
[TBL] [Abstract][Full Text] [Related]
4. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients.
Le Chevalier T; Brisgand D; Douillard JY; Pujol JL; Alberola V; Monnier A; Riviere A; Lianes P; Chomy P; Cigolari S
J Clin Oncol; 1994 Feb; 12(2):360-7. PubMed ID: 8113844
[TBL] [Abstract][Full Text] [Related]
5. Clinical pharmacokinetics of vinorelbine alone and combined with cisplatin.
Levêque D; Jehl F; Quoix E; Breillout F
J Clin Pharmacol; 1992 Dec; 32(12):1096-8. PubMed ID: 1336784
[TBL] [Abstract][Full Text] [Related]
6. [A late phase-II trial comparing KW-2307 with vindesine in non-small cell lung cancer (1). Lung cancer section in KW-2307 Study Group].
Furuse K; Yamori S; Negoro S; Fukuoka M; Takada Y; Nakai Y; Ikegami H; Fujii M; Nakajima S; Katakami N
Gan To Kagaku Ryoho; 1995 Jan; 22(1):67-76. PubMed ID: 7826080
[TBL] [Abstract][Full Text] [Related]
7. Do all patients with advanced non-small-cell lung cancer benefit from cisplatin-based combination therapy?
Soria JC; Brisgand D; Le Chevalier T
Ann Oncol; 2001 Dec; 12(12):1667-70. PubMed ID: 11843242
[TBL] [Abstract][Full Text] [Related]
8. [Clinical pharmacokinetics of vinca alkaloids].
Rahmani R; Samak R; Bore P; Cano JP
Bull Cancer; 1988; 75(2):195-200. PubMed ID: 3359064
[TBL] [Abstract][Full Text] [Related]
9. The cost-effectiveness of navelbine alone or in combination with cisplatin in comparison to other chemotherapy regimens and best supportive care in stage IV non-small cell lung cancer.
Evans WK; Le Chevalier T
Eur J Cancer; 1996 Dec; 32A(13):2249-55. PubMed ID: 9038606
[TBL] [Abstract][Full Text] [Related]
10. [A randomized comparative study of 254-S plus vindesine (VDS) vs. cisplatin (CDDP) plus VDS in patients with advanced non-small cell lung cancer (NSCLC)].
Furuse K; Fukuoka M; Asamoto H; Niitani H; Kimura I; Sakuma A; Yamaguchi Y
Gan To Kagaku Ryoho; 1992 Jul; 19(7):1019-26. PubMed ID: 1320846
[TBL] [Abstract][Full Text] [Related]
11. Combined effect of navelbine with medroxyprogesterone acetate against human breast carcinoma MCF-7 cells in vitro.
Sugiyama K; Shimizu M; Akiyama T; Ishida H; Okabe M; Tamaoki T; Akinaga S
Br J Cancer; 1998 Jun; 77(11):1737-43. PubMed ID: 9667641
[TBL] [Abstract][Full Text] [Related]
12. Antiproliferative activity of vinorelbine (Navelbine) against six human melanoma cell lines.
Photiou A; Sheikh MN; Bafaloukos D; Retsas S
J Cancer Res Clin Oncol; 1992; 118(4):249-54. PubMed ID: 1577845
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of antitumor activity of navelbine (vinorelbine ditartrate) against human breast carcinoma xenografts based on its pharmacokinetics in nude mice.
Tsuruo T; Inaba M; Tashiro T; Yamori T; Ohnishi Y; Ashizawa T; Sakai T; Kobayashi S; Gomi K
Anticancer Drugs; 1994 Dec; 5(6):634-40. PubMed ID: 7888700
[TBL] [Abstract][Full Text] [Related]
14. Synergistic Antitumor Efficacy Mediated by Liposomal Co-Delivery of Polymeric Micelles of Vinorelbine and Cisplatin in Non-Small Cell Lung Cancer.
Wang S; Gou J; Wang Y; Tan X; Zhao L; Jin X; Tang X
Int J Nanomedicine; 2021; 16():2357-2372. PubMed ID: 33790554
[TBL] [Abstract][Full Text] [Related]
15. [Properties of antitumor activity of vinorelbine tartrate, a new vinca alkaloid antitumor agent].
Kanazawa J; Morimoto M; Ohmori K
Nihon Yakurigaku Zasshi; 2000 Oct; 116(4):215-23. PubMed ID: 11084918
[TBL] [Abstract][Full Text] [Related]
16. Effective combination therapy of metastatic murine solid tumors with edatrexate and the vinca alkaloids, vinblastine, navelbine and vindesine.
Otter GM; Sirotnak FM
Cancer Chemother Pharmacol; 1994; 33(4):286-90. PubMed ID: 8281620
[TBL] [Abstract][Full Text] [Related]
17. Schedule-dependent interaction between vinblastine and cisplatin in Ehrlich ascites tumors in mice.
Cemazar M; Auersperg M; Scancar J; Kirbis IS; Pogacnik A; Sersa G
J Pharmacol Exp Ther; 2002 Jul; 302(1):337-43. PubMed ID: 12065735
[TBL] [Abstract][Full Text] [Related]
18. A three-arm trial of vinorelbine (Navelbine) plus cisplatin, vindesine plus cisplatin, and single-agent vinorelbine in the treatment of non-small cell lung cancer: an expanded analysis.
Le Chevalier T; Pujol JL; Douillard JY; Alberola V; Monnier A; Riviere A; Lianes P; Chomy P; Cigolari S; Besson F
Semin Oncol; 1994 Oct; 21(5 Suppl 10):28-33; discussion 33-4. PubMed ID: 7973766
[TBL] [Abstract][Full Text] [Related]
19. Schedule-dependent synergism of edatrexate and cisplatin in combination in the A549 lung-cancer cell line as assessed by median-effect analysis.
Perez EA; Hack FM; Webber LM; Chou TC
Cancer Chemother Pharmacol; 1993; 33(3):245-50. PubMed ID: 8269606
[TBL] [Abstract][Full Text] [Related]
20. [Antitumor activity of combination treatment combining gemcitabine with cisplatin or vindesine against human lung cancer xenografted in nude mice].
Fujita F; Fujita M; Fujita M; Sakamoto Y
Gan To Kagaku Ryoho; 1994 Nov; 21(15):2595-601. PubMed ID: 7979419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
